Nazlee Zebardast is an Ophthalmology physician affiliated with Massachusetts Eye and Ear Infirmary. OpenAlex indexes 167 publications with 2,560 citations (h-index 26).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
243 Charles St
Boston, MA 02114
Telephone
617-573-3689Registry record last updated 15 Aug 2018.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Allergan, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
83.1%Prostaglandin Analog36.7%Latanoprost87%Lumigan6%Travoprost3%Bimatoprost2%Tafluprost2%Part D<11 patientsCarbonic Anhydrase Inhibitor25.3%Dorzolamide-Timolol65%Dorzolamide Hcl19%Brinzolamide10%Acetazolamide3%Simbrinza3%Part D<11 patients+ 4 more classes in this area
Cardiovascular
12.8%Beta blocker12.8%Timolol Maleate95%Carteolol Hcl5%Part D<11 patientsMusculoskeletal
1.6%Cyclooxygenase Inhibitor1.6%Ketorolac Tromethamine100%Part D≥29 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Enhancing Glaucoma Risk Prediction through Advanced Genomics and Machine Learning
Massachusetts Eye and Ear Infirmary
FY2026$697,598R01EY036518 - Enhancing Glaucoma Risk Prediction through Advanced Genomics and Machine Learning
Massachusetts Eye and Ear Infirmary
FY2025$592,959R01EY036518 - Enhancing Glaucoma Risk Prediction through Advanced Genomics and Machine Learning
Massachusetts Eye and Ear Infirmary
FY2024$715,098R01EY036518
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phenome- and genome-wide analyses of retinal optical coherence tomography images identify links between ocular and systemic health
Science Translational Medicine
2024 - Polygenic Risk Scores for Glaucoma Onset in the Ocular Hypertension Treatment Study
JAMA Ophthalmology
2024 - Harvard Glaucoma Fairness: A Retinal Nerve Disease Dataset for Fairness Learning and Fair Identity Normalization
IEEE Transactions on Medical Imaging
2024 - Racial Disparities in Glaucoma Vision Outcomes and Eye Care Utilization: An IRIS Registry Analysis
American Journal of Ophthalmology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
John Kempen, MD
Massachusetts Eye and Ear Infirmary
Neil Bhattacharyya, MD, FACS
Massachusetts Eye and Ear Infirmary
Demetrios Vavvas, MD, PhD
Massachusetts Eye and Ear Infirmary
Evangelos Gragoudas, MD
Massachusetts Eye and Ear Infirmary
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”